Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.
Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of Medical Sciences, Zanjan 4513956184, Iran.
Molecules. 2019 Mar 15;24(6):1035. doi: 10.3390/molecules24061035.
Multiple factors are involved in the development of cancers and their effects on survival rate. Many are related to chemo-resistance of tumor cells. Thus, treatment with a single therapeutic agent is often inadequate for successful cancer therapy. Ideally, combination therapy inhibits tumor growth through multiple pathways by enhancing the performance of each individual therapy, often resulting in a synergistic effect. Polymeric nanoparticles prepared from block co-polymers have been a popular platform for co-delivery of combinations of drugs associated with the multiple functional compartments within such nanoparticles. Various polymeric nanoparticles have been applied to achieve enhanced therapeutic efficacy in cancer therapy. However, reported drug ratios used in such systems often vary widely. Thus, the same combination of drugs may result in very different therapeutic outcomes. In this review, we investigated polymeric co-delivery systems used in cancer treatment and the drug combinations used in these systems for synergistic anti-cancer effect. Development of polymeric co-delivery systems for a maximized therapeutic effect requires a deeper understanding of the optimal ratio among therapeutic agents and the natural heterogenicity of tumors.
多种因素参与癌症的发展及其对存活率的影响。许多因素与肿瘤细胞的化疗耐药性有关。因此，单一治疗药物的治疗通常不足以成功治疗癌症。理想情况下，联合治疗通过增强每种单独治疗的效果，通过多种途径抑制肿瘤生长，通常会产生协同作用。由嵌段共聚物制备的聚合物纳米粒子一直是联合递送与这些纳米粒子内的多个功能隔室相关的药物组合的热门平台。各种聚合物纳米粒子已被应用于提高癌症治疗的治疗效果。然而，此类系统中报道的药物比例差异很大。因此，相同的药物组合可能会导致非常不同的治疗结果。在这篇综述中，我们研究了用于癌症治疗的聚合物共递药系统以及这些系统中用于协同抗癌作用的药物组合。为了获得最大的治疗效果，开发聚合物共递药系统需要更深入地了解治疗剂之间的最佳比例以及肿瘤的天然异质性。
